Product Images Topiramate

This chart displays the cumulative rates for the time it takes for the first seizure to occur in two groups of participants taking different doses of topiramate. One group consists of 234 individuals receiving 50 mg/day of topiramate, while the other group comprises 236 individuals receiving 400 mg/day of topiramate. The x-axis represents time in days, ranging from 0 to 500 days, while the y-axis shows the cumulative rates of the participants experiencing their first seizure.*

The text is a table showing the impact of different dosages of Topiramate and a Placebo on migraine period rates in two studies. The table includes the average monthly migraine period rates, change from baseline to double-blind phase, and statistical significance indicators. The dosages evaluated were 50 mg/day, 100 mg/day, and 200 mg/day of Topiramate, along with a Placebo group. Study 10 and Study 11 are referenced. The results suggest that Topiramate at certain dosages may have a significant impact on migraine period rates.*

Description: This text provides information about Topiramate tablets USP, with each film-coated tablet containing 25mg of topiramate USP. It includes instructions for pharmacists to dispense the medication guide separately to each patient and to verify the prescription before dispensing. The dosage and usage details are mentioned in the accompanying prescribing information. It also indicates storage instructions, advising to keep the tablets in a tight, light-resistant container and store them at 20° to 25°C (68°to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F) to protect from moisture. The product is manufactured for Lupin Pharmaceuticals, Inc., located in Baltimore, Maryland, and by Lupin Limited located in Goa, India. Additionally, the text contains a United States code number and a LOT number.*

This is a description of Topiramate Tablets USP, each tablet containing Topiramate USP 25 g. The package includes 100 tablets with a unit dose of 2 tablets each. The medication guide is provided separately to each patient, and caution is advised for patients with depression. It is recommended to store the tablets at 20-25°C and protect them from moisture. The product is identified with National Drug Code (NDC) 68180-170-13.*

This description is for Topiramate tablets, NDC 68180-171-07, containing 50 mg of topiramate USP. The tablets are dispensed with a medication guide for each patient and should be stored in a light-resistant container at 20°C to 25°C (68°F to 77°F). It is manufactured by Lupin Pharmaceuticals, Inc. for Lupin Limited in India and is indicated for prescription use only. Please see the accompanying prescribing information for dosage and use details.*

This text provides information about a medication containing Topiramate USP 100 mg in film-coated tablets. It includes dosage instructions, storage guidelines, manufacturer details, and a caution for pharmacists to dispense the medication guide separately to each patient. It is important to keep the medication out of reach of children. The manufacturer is Lupin Pharmaceuticals, Inc. from Baltimore, Maryland, with manufacturing operations in India.*

This is a description of Topiramate Tablets USP packaging details. The text provides information regarding the dosage, usage instructions, storage conditions, caution for prescription, manufacturer details, and a code number. It also emphasizes keeping the medication out of reach of children. Topiramate is a commonly prescribed medication for conditions such as epilepsy and migraines. The text advises consulting a pharmacist or healthcare provider for additional guidance on medication usage.*

This is a description for Topiramate tablets USP. The medication guide should be provided individually to each patient by the pharmacist. Each film-coated tablet contains 200 mg of topiramate USP. It is essential that the prescription is verified before dispensing. The tablets should be kept in a light-resistant container at temperatures between 20°C to 25°C (68°F to 77°F). Storage is permitted between 15°C to 30°C (59°F to 86°F). Protect from moisture and keep out of reach of children. Manufactured by Lupin Pharmaceuticals, Inc. in Baltimore, Maryland, United States, for Lupin Limited in Goa, India.*

This is not-available.*